Home  »  Trending   »  Catalyst Pharmaceuticals Inc. (CPRX) and the Battl...

Catalyst Pharmaceuticals Inc. (CPRX) and the Battle of Fundamentals vs. Technicals

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) went down by -1.54% from its latest closing price compared to the recent 1-year high of $17.22. The company’s stock price has collected -9.21% of loss in the last five trading sessions.

Is It Worth Investing in Catalyst Pharmaceuticals Inc. (NASDAQ :CPRX) Right Now?

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) scored a price-to-earnings ratio above its average ratio, recording 26.77 x from its present earnings ratio. Plus, the 36-month beta value for CPRX is at 1.32. Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for Catalyst Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The average price from analysts is $16.90, which is $3.49 above the current price. CPRX currently public float of 94.95M and currently shorts hold a 6.55% ratio of that float. Today, the average trading volume of CPRX was 3.04M shares.

CPRX’s Market Performance

CPRX stocks went down by -9.21% for the week, with a monthly drop of -2.33% and a quarterly performance of 110.19%, while its annual performance rate touched 169.82%. The volatility ratio for the week stands at 9.35% while the volatility levels for the past 30 days are set at 6.72% for Catalyst Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is -6.55% for CPRX stocks with a simple moving average of 60.46% for the last 200 days.

Analysts’ Opinion of CPRX

Many brokerage firms have already submitted their reports for CPRX stocks, with ROTH Capital repeating the rating for CPRX by listing it as a “Neutral.” The predicted price for CPRX in the upcoming period, according to ROTH Capital is $15.50 based on the research report published on August 24th of the current year 2022.

CPRX Trading at 12.12% from the 50-Day Moving Average

After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.13% of loss for the given period.

Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 9.35%, as shares sank -3.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +75.98% upper at present.

During the last 5 trading sessions, CPRX fell by -9.21%, which changed the moving average for the period of 200-days by +91.57% in comparison to the 20-day moving average, which settled at $14.33. In addition, Catalyst Pharmaceuticals Inc. saw 98.08% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CPRX starting from Sundaram Preethi, who sale 18,214 shares at the price of $14.49 back on Sep 15. After this action, Sundaram Preethi now owns 0 shares of Catalyst Pharmaceuticals Inc., valued at $263,921 using the latest closing price.

GRANDE ALICIA, the VP, Treasurer and CFO of Catalyst Pharmaceuticals Inc., sale 50,000 shares at $15.57 during a trade that took place back on Sep 14, which means that GRANDE ALICIA is holding 357,442 shares at $778,650 based on the most recent closing price.

Stock Fundamentals for CPRX

Current profitability levels for the company are sitting at:

  • +37.20 for the present operating margin
  • +84.46 for the gross margin

The net margin for Catalyst Pharmaceuticals Inc. stands at +28.03. Equity return is now at value 25.10, with 22.40 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 7.76.

Is FedEx Corporation (FDX) a Keeper?

FedEx Corporation (NYSE:FDX) went up by 1.55% from its latest closing price compared to the recent 1-year high of $266.79. The company’s stock price has